Personalized med labeling may be cure for over-warning syndrome

The advent of personalized medicine should be accompanied by personalized risk messaging on drug labels, thus potentially marking a big step up from current messaging norms. For instance, blogs pharma industry watcher Mark Senak, is it necessary to still put "May make drowsy" "on the bottle even though I've been taking this medication daily for several years?" Several such messages adorned his med containers, "put on the side, around the bottom—anywhere a sticky could be stuck." The showstopper for him was "Discontinue use if pregnant." Senak ponders whether risk advisories that are irrelevant to the patient undermine the credibility of all warnings. Blog

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.